Trials / Withdrawn
WithdrawnNCT02271347
An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Jazz Pharmaceuticals · Industry
- Sex
- All
- Age
- 2 Months – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of Brincidofovir (BCV) when administered as an initial 200mg dose followed by 100mg twice weekly (BIW) for a total of 5 doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CMX001 | CMX001 administered as initial dose of 200mg then 100mg BIW for a total of 5 doses. |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2015-01-01
- Completion
- 2015-01-01
- First posted
- 2014-10-22
- Last updated
- 2015-02-02
Source: ClinicalTrials.gov record NCT02271347. Inclusion in this directory is not an endorsement.